The prognostic significance of inherited genetic variants in advanced-stage non-small cell lung cancer (NSCLC) patients remains unknown. In this study, we genotyped 271 817 singlenucleotide polymorphisms in 348 advanced NSCLC patients who received chemotherapy and analyzed their association with prognosis by using Cox proportional hazard regression model adjusted for known prognostic factors. Top candidate singlenucleotide polymorphisms (SNPs) were selected using the bootstrap re-sampling procedure. Median age of patient population was 56 years. Proportions of female, never smokers and adenocarcinoma were 64.9, 67.5 and 80.4%, respectively. We identified 17 top candidate SNPs related to prognosis using cut-off minimum P value of <5.0 × 10 -5 in at least 70% of 1000 bootstrap samples. These SNPs were located in the genomic regions of the ]. Survival differences according to the genotype of these SNPs were independent of sex, smoking, histology and chemotherapy regimens. These results suggested the variants at multiple genetic loci might contribute to the risk of death in advanced NSCLC patients receiving chemotherapy.
Introduction
Advanced or metastatic non-small cell lung cancer (NSCLC) has a poor prognosis with an overall 5-year survival rate of <4% (1) . However, recent advances in personalized risk stratification techniques have revealed that this tumor comprises a heterogeneous group of tumors that may have different biology and prognosis. Recently, accumulating evidence indicated that the survival outcomes of these patients could differ according to inherited genetic variations (2-11). The previous studies mainly reported that several genetic loci involved in the DNA repair genes such as XPD and XRCC1 or cell cycle-related genes have moderate associations with the prognosis of advanced NSCLC patients receiving platinum-based chemotherapy (2-8).
However, the results of the prior studies showed various and controversial effects of genetic variants. Even though candidate genes have functional significance that are potentially related to the prognosis, the limited number of candidate single-nucleotide polymorphisms (SNPs) and diverse clinical features may cause dissimilar results among studies. The survival outcomes of advanced-stage lung cancer patients are inevitably influenced by a variety of prognostic determinants such as the tumor's intrinsic aggressiveness, choice and efficacy of anticancer treatment, and underlying health condition of patient. Thus, to better evaluate the prognostic value of inherited genetic variations in this population, a more comprehensive approach that can simultaneously consider multiple possible genetic determinants is needed.
Our study aimed to investigate the prognostic significance and clinical characteristics of germline genetic variants detected by a genomewide single-nucleotide polymorphism (SNP) array in Korean patients with advanced NSCLC who were treated with systemic chemotherapy. Genotyping data from the patient cohort of our previously published genome-wide association study (GWAS) (12) were comprehensively analyzed with the corresponding clinical data including patient demographics, clinicopathological features and treatment outcomes. We applied the bootstrap re-sampling procedure to obtain robust and replicable results in this study (13) .
Patients and methods

Patient and data collection
We previously conducted a GWAS to identify susceptibility loci for NSCLC in the Korean population (12) . Among the 621 patients who were genomewide screened in that study, we selected 348 subjects for the current analysis by excluding patients with stages I-III disease (n = 198), those not receiving systemic chemotherapy (n = 28), those who received prior curative surgery or other therapy (n = 11) and those without available follow-up survival data available (n = 36) (Supplementary Figure 1 , available at Carcinogenesis Online). Subsequently, we reviewed patient's medical records and radiographic images to assess demographic and clinicopathological characteristics, chemotherapy regimens, tumor response and survival outcomes using a predesigned data collection format. This study was approved by the Institutional Review Board of the National Cancer Center (Goyang, Korea).
Genotyping and quality control
Blood samples were collected at the time of enrollment in the previous study (12) . After extracting genomic DNA from the peripheral blood, we genotyped 440 530 SNPs using the Affymetrix Genome-Wide Human SNP array 5.0 (Affymetrix, Santa Clara, CA). The study analysis focused on 271 827 SNPs that passed quality control filters including concordance rate for duplicates of at least 98%, call rate of at least 99%, minor allele frequencies of at least 0.05 and Hardy-Weinberg equilibrium of P > 1.0 × 10 -4 .
Statistical analysis
The association between each SNP and overall survival was analyzed using additive or dominant genetic models by the Cox proportional hazards regression model after adjusting for age, Eastern Cooperative Oncology Group (ECOG) performance status at diagnosis, smoking history, histology type, number of metastatic sites at diagnosis, use of platinum-based chemotherapy and use of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (EGFR-TKIs). A thousand test sets were generated using the bootstrap resampling procedure (13) . All 271 827 SNPs that passed quality control filters were used in the bootstrap re-sampling. We selected all SNPs with a minimum P value of <5.0 × 10 -5 from additive or dominant models in at least 70% of the 1000 bootstrap samples.
Pearson's χ 2 or Fisher exact test was used to determine the relationship between SNPs and categorical clinicopathological variables, where appropriate. Tumor response was retrospectively determined in accordance with the guideline established by the Response Evaluation Criteria in Solid Tumor (RECIST) committee (14) . The relationship between SNPs and tumor response was determined using logistic regression models adjusted for smoking history, tumor histology type and number of prior chemotherapy regimen. Progressionfree survival (PFS) was assessed from the first day of chemotherapy until the Abbreviations: CI, confidence interval; EGFR, epidermal growth factor receptor; HR, hazard ratio; LD, linkage disequilibrium; MST, median survival time; NSCLC, non-small cell lung cancer; PFS, progression-free survival; SNP, single-nucleotide polymorphism; TKI, tyrosine kinase inhibitors. first documentation of disease progression or death. Overall survival was calculated from the first day of chemotherapy until death or the most recent follow-up, which was censored at 5 years. Median survival time (MST) was estimated using the Kaplan-Meier method and survival differences between groups were assessed using the log-rank test. An interaction test was performed under the same Cox proportional hazards regression model. All the P values were two-sided. For the Bonferroni correction of 17 selected SNPs, 0.003 was set as the P value threshold for statistical significance. All the statistical analyses were performed using the R statistical computing package, the SAS system (SAS Institute, Cary, NC), or PLINK software (15) . Haploview was used to estimate the haplotype frequencies, the Lewontin's coefficients D′, and correlation coefficient r 2 (16) .
Results
Patient characteristics
The baseline characteristics of all patients are shown in Table I 
Genetic variants associated with survival
We observed 61 SNPs showing significant associations with overall survival in the original dataset (P < 5 × 10 -5
). However, only 23 of these 61 SNPs showed consistently strong relationship with overall survival in at least 70% of 1000 randomly sampled datasets (Table II) . The rs1571228 at 9p22.1 was highly linked with rs7853022, rs1571227 and rs4977472; the rs847845 at 6p21.31 with rs10947535 and rs2395601; and the rs2926702 at 8q13.3 with rs11993276, when r 2 ≥ 0.95 was defined as highly linked. After removing redundant SNPs, 17 SNPs were finally selected as top candidate SNPs to represent each gene locus related to overall survival. The significance of these associations ranged from P = 2.025 × 10 -7 to 1.185 × 10 ).
Subgroup analysis
The independent prognostic value of 17 candidate SNPs was further evaluated in more homogenous subgroups, such as the patients who were treated with platinum-based chemotherapy (n = 254), never smokers with adenocarcinoma histology (n= 215) or never smokers with adenocarcinoma histology who received EGFR-TKIs therapy (n = 178). A similar trend in the results was observed in the subgroup analyses although the P values increased due to fewer events (Supplementary Table S1 , available at Carcinogenesis Online).
Association with clinical characteristics
We tested the association of the top candidate SNPs with clinicopathological parameters including age, performance status, sex, smoking history, tumor histology type, number of metastatic organs and brain, bone or liver metastasis at diagnosis in the dominant genetic model (Supplementary Table S2 , available at Carcinogenesis Online). The minor variant alleles of rs8048207 located in the CDH8 gene at 16q22.1 had a high association with liver metastasis at diagnosis (CT+TT versus CC, 16.3% versus 5.2%, P = 0.001). All other gene variants except rs8048207 were not significantly related to clinicopathological characteristics.
The survival difference according to the genotype of the candidate SNPs except for rs1571228 was not significantly different between subgroups according to sex, smoking history and tumor histology type (Supplementary Table S3 , available at Carcinogenesis Online). However, the associations between rs1571228 at 9p22.1:FAM154A and prognosis were histology -dependent with more pronounced risk enhancement seen in non-adenocarcinoma histology group with HR (AG+GG to AA) of 0.27 (95% CI, 0.13-0.55) than in adenocarcinoma histology group with HR of 0.65 (95% CI, 0.50-0.84) (interaction of histology × SNP, P = 0.001).
Association with chemotherapy efficacy
The rs6510725 located near the MIER2 gene at 19p13.3 was significantly related to the treatment efficacy from EGFR-TKIs therapy. Patients carrying the variant allele showed higher tumor response rate Table S5 , available at Carcinogenesis Online). The survival benefit by EGFR-TKI treatment was not affected by genotypes of SNPs in EGF or MIER2 gene (Figure 2 ).
Discussion
Our genome-wide study identified 17 genetic variants having a possible association with prognosis in advanced NSCLC patients treated with systemic chemotherapy using the bootstrap re-sampling method. The associations between these SNPs and prognosis remained consistent in the subgroup analyses of more homogenous populations, namely the patients who were treated with platinum-based chemotherapy, never smokers with adenocarcinoma or never smokers with adenocarcinoma receiving EGFR-TKIs. The prognostic value of most SNPs did not change according to sex, smoking history, tumor histology type and the use of particular treatment regimens. These findings suggest that survivalrelated genetic variants identified by genome-wide study have independent prognostic significance in this population. Recently, two GWASs also reported genetic variants associated with survival of advanced NSCLC patients (10, 11) . A GWAS on a Caucasian population used a discovery scan of 327 advanced NSCLC patients receiving platinum-based chemotherapy and validated the results in two independent cohorts of 735 patients (10). They found two SNPs, rs1878022 and rs10937823, were replicated to be significant in each validation cohort. Additionally, a three-stage GWAS was conducted in Chinese Han populations (11). They identified five SNPs (rs7629386 at 3p22.1, rs969088 at 5p14.1, rs3850370 at 14q24.3, rs41997 at 7q31.31 and rs12000445 at 9p21.3) as markers for survival in 535 advanced NSCLC patients receiving platinum-based chemotherapy. However, these SNPs of two studies showed no significant association with prognosis of NSCLC in our study. The reason for the discrepancy may be due to the difference in the ethnic, demographic and clinical characteristics of patients between the studies.
Germline genetic variation can be involved at every stage of cancer progression. The majority of the identified prognostic SNPs in this study is located in LD blocks containing genes considered to play important roles in cancer development, progression and drug resistance (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (Supplementary Table S6 , available at Carcinogenesis Online). Furthermore, several different SNPs of genes implicated in this study have already been reported to be associated with cancer susceptibility and survival in other genome-based studies (31, 38) . In a recent GWAS of pancreatic cancer in a Japanese population, rs1427593 located in the THSD7B gene showed significant association with the risk of pancreatic cancer (P = 7.10 × 10 -6 ) (31). In addition, 
Prognostic SNP identified by GWAS in advanced NSCLC
the EGF gene has been exclusively studied as a cancer susceptibility gene because of its known biological functions in cellular growth, proliferation and differentiation (23) (24) (25) (39) (40) (41) (42) (43) (44) . Specially, +61A>G rs4444903 in the 5′-untranslated region of the EGF gene has been known as a functional polymorphism associated with the susceptibility of various cancer types including lung cancer, breast cancer, melanoma, gallbladder cancer and malignant glioma (24, (41) (42) (43) (44) . The 61*G allele seems to have a stronger promoter and produce more EGF protein than the 61*A allele (42, 45) . Moreover, the EGF A61G polymorphism has also been suggested to affect cancer survival (26, 27) . Another SNP, rs2237051, in the coding region of the EGF gene was associated with lung cancer survival in a Chinese population-based case-control pathway-oriented study (24) . The SNP rs881878, which is in strong LD with +61A>G EGF rs4444903, has been reported to decrease the risk of death in endometrial cancer (23) . Additionally, rs971696 located in the intron region of the EGF gene has been related to bladder cancer prognosis (25) . The SNPs in the EGF gene identified by our study are not in strong LD with those SNPs from other studies. However, all of our and previous results support the potential prognostic significance of SNPs in the EGF gene.
This study uncovered common clinical characteristics of prognostic genetic variants identified by GWAS. The majority of prognostic genetic variants were neither related to the baseline demographic characteristics of patients, such as age, sex and performance status nor the tumor parameters, such as tumor histology type and burden. Moreover, they were not associated with tumor response to particular chemotherapeutic drugs. However, some candidate SNPs showed distinct clinical features. First, the variant alleles of rs1571228 were more profoundly associated with improved survival in the patients with non-adenocarcinoma than in those with adenocarcinoma. This gene polymorphism is located in a poorly characterized FAM154A gene, which may play a role in cell growth because it was identified as a potential candidate variants associated with adult height in a Korean exome sequencing association study (46) . The interaction of this gene alteration and histology type warrants further study. Second, the variant genotype of rs8048207 located in the CDH8 gene was significantly associated with liver metastasis at diagnosis, which is a clinical marker for poor prognosis (47) , even though it may be an incidental observation. Additionally, a previous study showed that the CDH8 gene, which encodes a cell adhesion molecule related to cancer metastasis, was included in a 64-gene expression signature predicting survival of patients with stage I NSCLC (48) . Taken together, both CDH8 and liver metastasis appear to be associated with poor prognosis in lung cancer. Third, the variant allele of rs6510725 may be a favorable predictive marker for EGFR-TKIs as well as a favorable prognostic marker. We could not further investigate the relationship of this germline genetic variation and active somatic mutations in the EGFR tyrosine kinase gene due to the lack of tumor tissue sample. It remains to be elucidated whether gene variation may predispose EGFR mutational events.
Our findings should be interpreted with some reservation due to the nature of this type of correlation study. Most importantly, the sample size did not produce enough statistical power to show a genome-wide level significance. In addition, this study had no external validation cohort for replication analysis even though the resampling method was used as an alternative. Although it is not easy to collect subjects homogenous in terms of patient, tumor and treatment characteristics, further replication studies are needed to confirm the specific genetic markers found related to prognosis in this study. Nevertheless, the survival-associated SNPs from our study may provide clues to identify the target genes and functional variants at each locus. Thus, an additional genotyping of valuable SNPs from the candidate gene loci is needed in future study. The results from the fine mapping will produce promising clues to subsequent functional analyses.
In conclusion, genetic variants at multiple loci were found to be prognostically important for advanced NSCLC patients receiving chemotherapy, independent of histology type or treatment. Our collective findings will be helpful to determine truly functional and causative genetic variants associated with prognosis of advanced NSCLC patients. Eventually, further investigations into the biological relevance and clinical implication of these variants may assist clinical decision making for advanced NSCLC patients with poor prognosis.
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